Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.52 EUR | 0.00% | 0.00% | 0.00% |
May. 20 | JPMorgan raises target for Fresenius SE to 37.60 euros - 'Neutral' | DP |
May. 20 | FRESENIUS SE : JP Morgan remains Neutral | ZD |
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 11.13 for the current year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 16.83B | - | ||
+18.06% | 84.11B | C+ | ||
+2.04% | 27.25B | C+ | ||
-10.34% | 17.31B | B | ||
+3.49% | 15.92B | A- | ||
+1.50% | 13.68B | B- | ||
+72.64% | 13.29B | C- | ||
+72.24% | 12.73B | C+ | ||
+2.08% | 12.62B | A- | ||
+1.53% | 12.18B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FRE Stock
- 0OO9 Stock
- Ratings Fresenius